MARKET

ADAP

ADAP

Adaptimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.220
+0.070
+6.09%
Closed 17:20 12/11 EST
OPEN
1.150
PREV CLOSE
1.150
HIGH
1.300
LOW
1.130
VOLUME
440.63K
TURNOVER
--
52 WEEK HIGH
6.31
52 WEEK LOW
0.7090
MARKET CAP
128.29M
P/E (TTM)
-0.8883
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADAP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADAP News

  • Adaptimmune gets FDA designation to accelerate development of cancer therapy
  • American City Business Journals.12/03 19:20
  • Adaptimmune's ADP-A2M4 nabs RMAT tag for rare soft tissue cancer
  • Seeking Alpha - Article.12/03 17:31
  • Regenerative Medicine Advanced Therapy Designation Granted By FDA To Adaptimmune's ADP‑A2M4 For Treatment Of Synovial Sarcoma
  • Benzinga.12/03 13:33
  • Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADPA2M4 for the Treatment of Synovial Sarcoma
  • GlobeNewswire.12/03 13:30

More

Industry

Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About ADAP

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
More

Webull offers Adaptimmune Therapeutics PLC - ADR (ADAP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.